able, raltegravir, the first HIV-1 integrase inhibitor, seems to be a favorable candidate to replace enfuvirtide within a virologically suppressive salvage regimen. Indeed, raltegravir has a potent antiviral activity both in treatment-naive and treatmentexperienced patients [6] [7] [8] [9] . Raltegravir is taken orally twice daily, has a good safety profile, and has a low potential for drug interactions. As a member of a new class of antiretroviral drugs, raltegravir, like enfuvirtide, remains active against viruses with protease inhibitor-and reverse-transcriptase inhibitor-associated mutations.
A few pilot studies have reported that a switch from enfuvirtide to raltegravir in patients receiving a virologically suppressive regimen could be successful [10] [11] [12] . However, these studies involved a limited number of patients and did not use a randomized design. The aim of our study was to determine, among patients with multidrug-resistant HIV-1 infection virologically suppressed with an enfuvirtide-based antiretroviral regimen, whether a switch to raltegravir was as effective and well tolerated as the maintenance of enfuvirtide.
METHODS

Patients.
Eligible patients were HIV-1-infected adults with a history of triple class (protease inhibitor [PI] , nucleoside reverse-transcriptase inhibitor [NRTI] , and nonnucleoside reverse-transcriptase inhibitor [NNRTI] ) failure or intolerance who had achieved virologic suppression with an enfuvirtidebased regimen, with plasma HIV-1 RNA levels !400 copies/mL for 13 months. Patients were integrase-inhibitor naive. There was no CD4 T cell count restriction. Patients were required to have blood cell and serum chemistry values within acceptable ranges. Major exclusion criteria were pregnancy, breast-feeding, and concomitant treatment with rifampin, rifabutin, phenytoin, or phenobarbital.
Study design. The study was a multicenter, randomized, comparative, 48-week open-label trial with a primary end point at week 24, performed at 39 Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) sites in France. The protocol was approved by the ethics committee CPP Paris I Hô tel Dieu. All patients gave written informed consent. Patients were randomly assigned 1:1 to either maintain their enfuvirtide-based regimen or a switch to raltegravir in combination with the same background regimen. Raltegravir was given orally twice daily (one 400-mg pill twice daily) without regard to food, and enfuvirtide was given twice daily (one 90-mg subcutaneous injection twice daily). In the enfuvirtide maintenance arm, after reaching the primary efficacy end point at week 24, patients were offered to switch to a raltegravir-based regimen up to week 48. The first 24 weeks of this trial, during the randomized comparison between arms, are the focus of this report.
Study monitoring. Patients were assessed at baseline, week 2 (only in the raltegravir arm), week 4, week 8, and every 8 weeks thereafter up to week 24. At each visit, clinical data were collected through an interim medical history and physical examination, and blood specimens were obtained. Routine analyses were performed at each visit, including a complete blood count, CD4 cell counts, plasma HIV-1 RNA levels (lower limit of detection, 50 copies/mL), and tests for liver, kidney, muscle, and pancreatic function. Fasting lipid (total and high-density lipoprotein cholesterol and triglycerides) and glucose levels were also measured at baseline and at week 24. At each ANRS site, the virology laboratories were participating in a quality control program, and the same assay was used to monitor plasma HIV-1 RNA levels at all sites. When a plasma HIV-1 RNA level у400 copies/mL was detected at a visit, a second sample was obtained two weeks later for confirmation of virologic failure. In patients experiencing virologic failure, a genotypic resistance test was performed, according to the consensus method of the ANRS resistance group [13] . Mutations associated with drug resistance were defined according to the International AIDS Society-United States drug resistance mutations group definition [14] . Safety was assessed through the reporting of adverse events and laboratory abnormalities, the severity of which was assessed with use of the ANRS toxicity grading scale.
Study end points. The primary efficacy end point was the cumulative proportion of patients with virologic failure, defined as a confirmed plasma HIV-1 RNA level у400 copies/mL during the 24 weeks of the study. Patients with a last available plasma HIV-1 RNA measurement of у400 copies/mL without confirmation or who changed antiretroviral therapy after a single plasma HIV-1 RNA measurement у400 copies/mL were also considered to have experienced virologic failure.
Secondary end points included the time to virologic failure, the proportion of patients with plasma viral loads !50 and !400 copies/mL throughout the study period, changes from baseline in CD4 T cell counts, the proportion of patients who experienced AIDS-defining clinical events or death [15] , and the proportion of patients who discontinued the treatment strategy assigned at randomization (discontinuation of enfuvirtide in the enfuvirtide arm and discontinuation of raltegravir or reinitiation of enfuvirtide in the raltegravir arm).
Safety end points included the proportions of patients with mild (grade 1) to severe (grade 4) clinical adverse reactions and laboratory abnormalities. An independent Data Safety Monitoring Board monitored safety and efficacy data throughout the study.
Statistical analysis. A sample size of 85 patients per arm was required to establish non-inferiority of the raltegravir arm as compared with the enfuvirtide arm, on the basis of an expected virologic failure rate of 4% in the enfuvirtide arm [16] , a margin of non-inferiority of 10%, with a 2-sided a level of 0.05, and a statistical power of 80%. The primary efficacy anal- a One patient was disappointed by his randomization group, and discontinued enfuvirtide at baseline without experiencing virologic failure; b this patient temporarily discontinued antiretroviral therapy including enfuvirtide and resumed therapy after experiencing virologic failure; c this patient discontinued the trial at week 16 and was censored at that time; d this patient wished to become pregnant, withdrew consent before baseline, did not start the assigned treatment, and was not included in the analysis. ysis was to compare the crude proportions of patients in the 2 arms who reached the primary study end point with use of the Farrington-Manning method. Non-inferiority was established if the upper limit of the 95% 2-tailed confidence interval (CI) of the difference in proportions between groups was р10%.
The primary efficacy end point was analyzed on an intentionto-treat basis, including all patients who started the assigned study drugs (ie, raltegravir or enfuvirtide). An on-treatment analysis was also performed, censoring patients who discontinued study drugs. Missing data from patients who withdrew consent, were lost to follow-up, or died were censored without imputation.
x 2 tests or Fisher's exact tests were used to compare categorical variables between the arms. Differences in continuous variables between arms were analyzed with the use of nonparametric Wilcoxon rank-sum tests. Comparisons were made with use of a 2-sided a level of 0.05. Statistical analyses were performed with the use of SAS software (SAS Institute).
RESULTS
Population. From June 2007 through September 2007, 193
patients underwent screening procedures, 170 were found eligible for randomization into the study, and 1 was excluded from the analysis because she withdrew consent before randomization ( Figure 1 ). The baseline characteristics of the remaining 169 patients were well balanced between the arms (Table 1) . Overall, 168 patients (99%) completed 24 weeks of follow-up, with only 1 patient discontinuing the study. Patients were mostly men (85%) with a median age of 48 years who were heavily treatment experienced, with a median duration of antiretroviral therapy of 13.6 years and a median duration of enfuvirtide of 2.3 years before randomization. Treatment regimens at baseline included enfuvirtide, at least 1 NRTI (95%), 1 or 2 PIs (99%), and 1 NNRTI (8%).
Study end points. For the primary end point, in the intention-to-treat analysis, the proportion of patients with virologic failure was 1.2% in each arm, corresponding to only 1 patient who experience failure per arm. The difference between treatments (raltegravir minus enfuvirtide) was 0.01% (95% CI, Ϫ6.7 to 6.8%;
). P ! .002 In the raltegravir arm, the patient who experienced virologic failure had AIDS and started receiving enfuvirtide 6 years before randomization. A genotype analysis performed at the time of enfuvirtide initiation documented resistance mutations D67N, K70R, K101E, M184V, T215F, and K219Q in the reverse-transcriptase and mutations L10I, K20R, V32I, M36I, M46I, I47V, F53L, I54M, L63P, A71L, G73S, and L90M in the protease. He had been receiving the same combination of lamivudine, nevirapine, fosamprenavir/ritonavir, and enfuvirtide for 3 years before randomization, with a viral load always suppressed !50 copies/mL. At baseline, he switched from enfuvirtide to raltegravir while continuing to receive the same background regimen. His CD4 cell count was 452 cells/mL. His plasma HIV-1 RNA level then increased to 969 copies/mL at week 8 and to 2391 copies/mL 2 weeks later. Emergence of new mutations K103N and G190A, which are associated with NNRTI resistance, and mutations V11I, K20I, A71V, and L89V, which are associated with PI resistance, were detected in the genotype analysis performed 13 days after virologic failure. No raltegravir or enfuvirtide resistance mutations were detected. The patient resumed enfuvirtide in combination with lopinavir/ritonavir and tenofovir/emtricitabine but failed to again achieve suppression of plasma HIV-1 replication. Figure 2 . Proportion of patients (with 95% confidence intervals) with a plasma human immunodeficiency virus (HIV) RNA level !50 copies/mL over 24 weeks in the raltegravir (RAL) and enfuvirtide (ENF) arms of the EASIER ANRS 138 study (intention-to-treat analysis). Differences were not statistically significant ( ) at week 24. P p .81 Figure 3 . Median CD4 cell counts (with interquartile ranges) in patients randomly assigned to receive raltegravir (RAL) and enfuvirtide (ENF) over 24 weeks in the EASIER ANRS 138 study (intention-to-treat analysis). Differences were not statistically significant ( ) at week 24. P p .31
In the enfuvirtide arm, the patient who experienced virologic failure started antiretroviral therapy 15 years before randomization and had been receiving a combination of didanosine, abacavir, darunavir/ritonavir, and enfuvirtide for 1 year. At baseline, his viral load was !50 copies/mL, and his CD4 cell count was 597 cells/mL. Plasma HIV-1 RNA levels remained !50 copies/mL from baseline to week 8. He then left to travel abroad and had discontinued therapy for 3 weeks when he came back for the week 16 visit, and his plasma HIV-1 RNA level was 1,584,893 copies/mL. The patient then resumed therapy including enfuvirtide, but his plasma HIV-1 RNA level 3 weeks later was still 15,845 copies/mL, thus defining virologic failure. No emergent mutation was detected in the genotype analysis performed 24 days after virologic failure. At week 24, viral load had decreased to 200 copies/mL with the same regimen.
The primary efficacy end point was also assessed in an ontreatment analysis, censoring patients who discontinued study drugs. In this analysis, the proportion of patients who experienced virologic failure was 1.2% and 0% in the raltegravir and enfuvirtide arms, respectively. The treatment difference (raltegravir minus enfuvirtide) was 1.22% (95% CI, Ϫ5.6 to +8.1%;
). The upper bound of the CI was again below P ! .001 the predefined non-inferiority threshold of 10%, demonstrating the non-inferiority of the raltegravir arm, compared with the enfuvirtide arm.
The proportion of patients with a plasma HIV-1 RNA level !50 copies/mL at week 24, a secondary virologic end point, was very similar in both arms (88% in the enfuvirtide arm vs 89% in the raltegravir arm; ) ( Figure 2 ). There were no P p .81 significant differences between the arms in the median CD4 cell counts over time (Figure 3) . At 24 weeks, the median increases from baseline were +15 and +11 CD4 cells/mL in the enfuvirtide and the raltegravir arms, respectively ( ). No P p .31 patient experienced a progression to AIDS during the study, and only 5 patients (1 in the enfuvirtide arm vs 4 in the raltegravir arm;
) experienced minor HIV-1-related P p .17 infection.
Safety and tolerability. There was no difference between arms in the overall incidence of patients experiencing grade 1-4 adverse reactions during the 24 weeks of the study (78% in the enfuvirtide arm vs 80% in the raltegravir arm;
). P p .74 Furthermore, no significant difference was observed in the incidence of patients who experienced grade 3-4 adverse reactions (8% in the enfuvirtide arm vs 13% in the raltegravir arm; ) ( Table 2 ). There was, however, a higher incidence of P p .31 patients who experienced grade 1-4 laboratory abnormalities in the raltegravir arm (71%), compared with the enfuvirtide arm (46%;
). This difference was mainly related to a P p .001 higher incidence of neutropenia (11% vs 2%) and increased levels of alkaline phosphatases (14% vs 8%), gammaglutamyl transferases (37% vs 16%), and transaminases (25% vs 16%) in the raltegravir arm versus the enfuvirtide arm (data not shown). There was also a trend toward a higher incidence of patients experiencing emerging grade 3-4 laboratory abnormalities in the raltegravir arm (14%), compared with the enfuvirtide arm (7%; ) ( Table 2 ). In particular, 2 patients, P p .13 both in the raltegravir arm, experienced a grade 4 alanine aminotransferase increase between weeks 4 and 16 and required raltegravir discontinuation. Both patients were receiving a tipranavir-containing regimen. Tipranavir was then switched for darunavir, and raltegravir could be resumed without further increase in alanine aminotransferase levels or virologic failure. No patients in the enfuvirtide arm discontinued enfuvirtide because of adverse reactions or laboratory abnormalities.
Week 24 changes from baseline in fasting lipid and glucose levels could only be assessed in patients from whom fasting blood samples were obtained (Table 3) . There was no difference in glucose levels between treatment arms. However, the median increases from baseline in triglyceride and total cholesterol levels were significantly higher in the raltegravir arm, compared with the enfuvirtide arm.
DISCUSSION
This study showed that, in patients with multidrug-resistant HIV-1 infection, a switch from enfuvirtide to raltegravir within a virologically suppressive regimen was successful in maintain-ing inhibition of plasma HIV-1 replication through 24 weeks. Indeed, in the intention-to-treat analysis, only 1.2% of patients in both the raltegravir and the enfuvirtide arms experienced virologic failure (upper bound of the 95% CI for the difference between raltegravir and enfuvirtide, 6.8%). Similarly, in the ontreatment analysis, 1.2% and 0% of patients in the raltegravir and enfuvirtide arms, respectively, experienced virologic failure (upper bound of the 95% CI for the difference between raltegravir and enfuvirtide, 8.1%). Therefore, in this patient population, the switch to raltegravir was virologically non-inferior to the maintenance of the enfuvirtide-based suppressive regimen. This result therefore confirms and expands the results from previous pilot studies [10] [11] [12] . In addition, the proportion of patients with a plasma HIV-1 RNA level !50 copies/mL remained stable in both arms of the study throughout the 24 weeks, with no trend toward a better antiviral activity in the raltegravir arm (Figure 2 ). Long-term follow-up data will therefore be important to confirm the sustainability of virologic suppression after the switch to raltegravir. Indeed, recent data from the SWITCHMRK study revealed that a switch from lopinavir/ritonavir to raltegravir in combination with only 2 NRTIs did not maintain virologic suppression and was associated with a high rate of raltegravir-associated resistance mutations [17] . However, in our study, although patients had experienced multiple treatment failures, they received a boosted PI and NRTIs in addition to raltegravir, and this more robust background treatment regimen might explain the differences in outcome between the studies. Of note, the only patient who experienced virologic failure in our trial was randomized to the raltegravir arm, and the emergence of new resistance mutations to NNRTIs and PIs prevented the suppression of viral replication when the enfuvirtide-based regimen was resumed. Although no raltegravir resistance was detected, this case is a reminder that patients should be closely monitored during the switch to raltegravir.
The switch to raltegravir was not associated with better outcomes in CD4 cell counts or HIV-1 disease progression in this study. There is no doubt however, that this switch to an oral drug is more convenient than the maintenance of a drug regimen that requires twice-daily subcutaneous injection with the associated painful nodules. Preliminary data from quality-oflife studies have shown an improvement in patient satisfaction, and ongoing studies will probably confirm this finding [11] .
As reported in other trials involving treatment-experienced patients, the clinical tolerability of raltegravir was good in this study, and the incidence of clinical adverse events throughout the 24-week duration of the trial was similar in both arms, with no clear treatment-related toxicity [7, 9] . Indeed, only 8% of patients in the enfuvirtide arm and 13% in the raltegravir arm experienced grade 3-4 clinical adverse events.
A higher incidence of patients experiencing laboratory abnormalities was reported during this trial in the raltegravir arm (71%), compared with the enfuvirtide arm (46%; ). P p .001 This difference was mainly attributable to a higher incidence of liver enzyme increases in the raltegravir group. The incidence of patients who experienced grade 3-4 laboratory abnormalities in the raltegravir arm remained low (14%) but was still higher than that in the enfuvirtide arm (7%; ) ( Table 2) . Of P p .13 note, 2 patients who were randomized to the raltegravir arm had to temporarily discontinue this drug because of increases in transaminase levels. Both patients were receiving a regimen containing tipranavir, which is known to be associated with significant liver toxicity [18] . After the switch from tipranavir to darunavir, raltegravir was resumed in these patients without further increases in transaminase levels. These cases raise the issue of a potential liver toxicity with the combination of raltegravir and tipranavir/ritonavir. However, such events were not reported to occur more frequently in phase III trials of raltegravir among treatment-experienced patients receiving tipranavir/ritonavir, compared with other PIs [7, 8] . Additionally, there are no data to suggest pharmacokinetic interactions that would result in higher drug exposure when tipranavir/ritonavir and raltegravir are coadministered. Rather, limited pharmacokinetic data have reported that tipranavir may reduce raltegravir trough levels by 55% and that enfuvirtide could increase tipranavir levels by 31%, which would suggest that the switch to raltegravir could be associated with decreased tipranavir levels [19] [20] [21] . Formal pharmacokinetic studies should therefore be performed to address this issue. Pending the results of these analyses, the coadministration of raltegravir in patients already receiving tipranavir/ritonavir should be carefully monitored. In addition, in this trial, the switch to raltegravir was associated with a slight increase in total cholesterol and triglyceride levels, and the difference between the 2 groups was statistically significant (Table 3 ).
In conclusion, we have shown that a switch from enfuvirtide to raltegravir within a virologically suppressive regimen in patients with multidrug-resistant HIV-1 infection is effective and well tolerated, at least over 24 weeks. This regimen offers the advantage of simplicity and represents an attractive therapeutic option for these patients. Long-term follow-up of these patients is required. 
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